An observational study in Ryanodine Receptor 1-Related Myopathy and Ryanodine Receptor 1 Related Disorders, sponsored by National Institutes of Health Clinical Center (CC). Recruiting at 1 site in United States. Open to participants aged 7 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by National Institutes of Health Clinical Center (CC) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies in Muscular Diseases with a site in United States — 19 open to participants now, 27 under way, 5 of them phase 3. Muscular Diseases · United States.
Among the 99 studies in Muscular Diseases with a site in United States, this one is the 11th largest by planned enrollment of the 30 observational ones that give a count, is one of 6 that started in 2025, is one of 31 observational ones, reaches primary completion later than 22 of the 25 other live ones, and was the 83rd registered.
232 studies on the registry are indexed under Muscular Diseases; 54 are open to participants now.
Browse Muscular Diseases studies →19 of the 99 studies in Muscular Diseases with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18+ · Healthy volunteers
AstraZeneca · Sites in United States, Argentina, Australia and 32 more countries
Ages 5–80
University of Alabama at Birmingham · Sites in United States
Ages 16+
AstraZeneca · Sites in United States, Canada, China and 7 more countries
Ages 18–70
Kite, A Gilead Company · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 38 Muscular Diseases studies recruiting now, 21 (55%) set no upper age limit and 10 (26%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.
This study: 7 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 18 · Phase 3 16 · Phase 4 4
First in 1984; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 95 across 85 observational studies indexed under Muscular Diseases.
Median enrollment 38 across the 66 interventional studies, 70 across the 30 observational. Of the 63 that completed or were terminated, 31 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 99 have an industry lead sponsor. The 10 most frequent:
National Institutes of Health Clinical Center (CC) is the lead sponsor of 376 studies on the registry; 27 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 19 (83%) have results posted.
National Institutes of Health Clinical Center (CC) has 1 study filed under Muscular Diseases — fewer than ten, so there is no comparison to draw.
8 of the studies in Muscular Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06599697University of Alabama at BirminghamThe MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy | 2026-12-30 |
| NCT06374719Clinic for Special ChildrenWiTNNess - TNNT1 Myopathy Natural History Study | 2027-01-01 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
| NCT06916806AstraZenecaA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | 2027-05-05 |
| NCT02842424University of NebraskaRamipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis | 2027-06 |
Add all 8 to your calendar (.ics) → With an account.
Among the 99 studies in Muscular Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background:
Congenital myopathies (CM) are genetic disorders that can cause decreased muscle tone and muscle weakness. Most CMs in the United States are related to the ryanodine receptor 1 (RYR1) gene. Researchers need more natural history data to learn about these CMs in children and adults.
Objective:
To learn more about the signs, symptoms, and course of RYR1-related disorders.
Eligibility:
People aged 7 years and older with an RYR1-related disorder.
Design:
Ambulatory participants will come to the Clinical Center and non-ambulatory participants will visit via telehealth.
Visits will be once a year for 3 or 5 years. Clinical Center visits will take 2 to 3 days.
All participants will undergo tests including:
Photos and videos. These will be taken to document the participant s condition.
Blood and urine tests.
Activity Tracker. Participants will wear a device to record their activity.
Questionnaires. Participants will answer questions about their health, pain, fatigue, stress, quality of life, and other topics.
Participants who visit the Clinical Center will also undergo:
Tests of heart and lung function.
Motor skills and strength tests. Participants will walk, climb stairs, kneel, crawl, stand up, and perform other movements to test their strength and abilities. They will squeeze and pinch a handheld device to test their grip.
Imaging scans.
Skin biopsy. Adult participants may opt to have a sample of skin taken (one time only).
Eye exam
STUDY DESCRIPTION:
This prospective natural history study seeks to characterize the clinical manifestations and course of Ryanodine Receptor 1 -related disorders (RYR1-RD). RYR1-RD include a wide range of rare congenital and adult-onset neuromuscular phenotypes that are typically slowly progressive. The study is observational and comprises a primary data collection phase (Years 1-3) and extended follow-up phase (Years 4-5), stratified into centralized (ambulatory) and decentralized (non-ambulatory) arms. During each phase, there will be one visit per year. The study will enhance the foundational knowledge of RYR1-RD and support clinical trial readiness.
OBJECTIVE:
Primary:
Characterize phenotype and disease course over a three-year period
Secondary:
Characterize phenotype and disease course over an extended (2-year) period (total 5 years)
Exploratory:
Extract common data elements from existing medical records (real-world evidence)
ENDPOINTS:
Primary:
Change from baseline to Year 3 in:
Motor function and performance
Pulmonary function
Patient-reported outcomes
Ophthalmology
Secondary:
Change from baseline to Year 5 in:
Motor function and performance
Pulmonary function
Patient-reported outcomes
Ophthalmology
Exploratory:
Biomarkers
Including but not limited to:
A total of 150 clinically stable adults and children (7 years of age or older) with genetically confirmed RYR1-RD.
INCLUSION CRITERIA (CENTRALIZED ARM)
EXCLUSION CRITERIA (CENTRALIZED ARM)
INCLUSION CRITERIA (DE-CENTRALIZED ARM)
EXCLUSION CRITERIA (DE-CENTRALIZED ARM)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Visits are conducted at the NIH clinical center. All participants are ambulatory.
Visits are conducted via telehealth.
Adverse and disease-related events
Serious (21CFR312.32) adverse events:- Narrative description (clinician)- Causality assessment (related or unrelated to disease)- CTCAE system organ class- CTCAE lower-level term- Falls questionnaire; adults
Time frame: 3 years
Medical data review
\- Demographics- Developmental history- Medical history- Social determinants of health (environmental conditions such as economic stability, health care and education access and quality, neighborhood and built environment, and social and community context.- Full physical exam- Review of genetic diagnostic report/results- Prior medical records
Time frame: 3 years
Ophthalmology
\- Marginal reflex distance (Ptosis)- Binocular horizontal visual field test- Optical Coherence Tomography- Goldmann Perimetry Degrees: lateral rectus, superior rectus, inferior oblique, medial rectus, superior oblique, inferior rectus
Time frame: 3 years
Patient-reported outcomes
\- PROMIS-57 Profile (subscale and overall t-scores); adults - depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and satisfaction with participation in social roles- PROMIS Ped-25 Profile (subscale and overall t-scores); 8 - 17 y- PROMIS Parent Proxy 25 Profile - Fatigue, physical stress experiences, positive affect and wellbeing, psychological stress experiences, anxiety/fear, physical function, pain; 5 - 7 y- PROMIS Upper Extremity - Short Form 7a- PROMIS Pediatric Upper Extremity - Short Form 8a- PROMIS Parent Proxy Upper Extremity - Short Form 8a- Physical Activity Questionnaire for Children (PAQ-C); 8 - 13 y- Physical Activity Questionnaire for Adolescents (PAQ-A); 14 - 17 y- International physical activity questionnaire (IPAQ); adults
Time frame: 3 years
Pulmonary function
\- Forced vital capacity (% reference norm)- Forced expiratory volume at 1 second (% reference norm) - Slow vital capacity (Liters)- Maximal voluntary ventilation (Liters)- Maximum inspiratory pressure (MIP)- Maximum expiratory pressure (MEP)
Time frame: 3 years
Motor function and performance
\- Motor Function Measure (MFM) sub-domains (percent of maximum score)- Six-minute walk test (meters travelled with percent predicted)- Timed functional tests (ascend four stairs, descend four stairs, supine to stand) (seconds)- Grip and pinch strength (kg and percent predicted)- Performance of Upper Limb (PUL)- Accelerometry (wearable sensor)- Quantitative muscle assessment- Brooke and Vignos assessment
Time frame: 3 years
Characterize phenotype and disease course over an extended (2-year) period (total 5 years).Collect exploratory biomarker data.
(1) Investigate potential biomarkers of disease status and progression(2) Explore clinical meaningfulness thresholds for research assessments(3) Extract common data elements from existing medical records (real-world evidence)
Time frame: 5 years
Plan to share: Undecided
Started Mar 2025 (actual). Primary completion is estimated for Apr 2031, 73 months after the start.
Of 36 observational studies under Muscular Diseases, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 159. This study's planned 73 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institutes of Health Clinical Center (CC) →